bnt162
Secondary Progressive Multiple Sclerosis
Novartis PharmaceuticalsvaccinePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 89/ 100
Competitive context
35 Active assets in the Secondary Progressive Multiple Sclerosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Siponimod Novartis Pharmaceuticals | Phase 4 | BBB |
Fampridine University College Dublin | Phase 4 | BBB |
Rituximab Cairo University | Phase 3 | BB |
mis416 Innate Immunotherapeutics | Phase 2 | BB |
Natalizumab Biogen | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →